ACP-211 vs Esketamine (CLE-100)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Major Depressive Disorder

Shared mechanism: NMDA receptor · full Major Depressive Disorder pipeline

ACP-211

Developed by Acadia Pharmaceuticals

Phase 2 in Major Depressive Disordersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: August 2027 · NCT07284667 (registry estimate)

No aligned efficacy figure on record for this race.

Esketamine (CLE-100)

Developed by Clexio Biosciences

Phase 2 in Major Depressive Disordersmall molecule
Partial signal

NCT04103892 · Phase 2 · completed

The study randomized 146 participants overall, including 130 in the main Part B comparison, to double-blind CLE-100 or placebo alongside standard antidepressant treatment. Its clinical MADRS primary endpoint was missed: the improvement with CLE-100 was not significantly different from placebo (p=0.46), so the trial provides well-controlled but inconclusive evidence.

Reported efficacy

Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score (29 days): CLE-100 -11.66 units on a scale (Standard Error 1.5) vs Placebo -8.7 units on a scale (Standard Error 1.55) (missed)

Result source: NCT06340958

Results for Major Depressive Disorder

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointACP-211Esketamine (CLE-100)
MADRS, change (acute)—Not reported-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892
CGI-S, change (acute)—Not reported—Not reported
MADRS response—Not reported—Not reported
MADRS remission—Not reported—Not reported
Relapse (% of patients)—Not reported—Not reported

MADRS, change (acute)

ACP-211
—Not reported
Esketamine (CLE-100)
-10.7 vs -9.5−1.3 vs placebowk 4.14 · n 70NCT04103892
2 other results
  • -11.7 vs -8.7 wk 4.14 · n 50 · Phase 2 · primary NCT06340958
  • -13.0 vs -7.7 wk 4.14 · n 35 · Phase 2 · secondary NCT04103892

CGI-S, change (acute)

ACP-211
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS response

ACP-211
—Not reported
Esketamine (CLE-100)
—Not reported

MADRS remission

ACP-211
—Not reported
Esketamine (CLE-100)
—Not reported

Relapse (% of patients)

ACP-211
—Not reported
Esketamine (CLE-100)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

ACP-211: no structured comparison results are available for Major Depressive Disorder.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. ACP-211: 0 of 4 rows · Esketamine (CLE-100): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEsketamine (CLE-100)
Dropout rate
7.7%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
8.3%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
20%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Discontinued due to AEs
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
8%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Serious AEs
0%Part A - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
0%Part B - CLE-100 (Oral Esketamine)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
2%
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
Most frequent reported AEs
dizziness 30.8% (placebo 0%)
somnolence 15.4% (placebo 0%)
alanine aminotransferase increased 7.7% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
dizziness 13.9% (placebo 0%)
headache 12.5% (placebo 0%)
somnolence 11.1% (placebo 0%)
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
dizziness 18% (placebo 4.1%)
nausea 18% (placebo 0%)
headache 12% (placebo 2%)
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Esketamine (CLE-100)

MADRS -10.72 vs -9.46 placebo score @ 4.14wk
absolute change · score
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
show 2 more results
-12.96 vs -7.68 placebo score @ 4.14wk
NCT04103892 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2
-11.66 vs -8.7 placebo score @ 4.14wk
NCT06340958 · Phase 2 · monotherapy · Major Depressive Disorder · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACP-211's landscape · Esketamine (CLE-100)'s landscape